The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2019

Filed:

Jan. 16, 2019
Applicants:

The Board of Trustees of the University of Arkansas, Little Rock, AR (US);

Ochsner Clinic Foundation, New Orleans, LA (US);

National University Corporation Kagawa University, Kagawa, JP;

Inventors:

Robert C. Gensure, Lexington, MA (US);

Joshua Sakon, Fayetteville, AR (US);

Osamu Matsushita, Okayama, JP;

Tulasi Ponnapakkam, Metairie, LA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); C07K 14/635 (2006.01); C12N 9/10 (2006.01); C12N 9/64 (2006.01); C12N 9/50 (2006.01); A61K 35/28 (2015.01); A61K 38/16 (2006.01); A61K 8/64 (2006.01); A61K 8/66 (2006.01); A61K 38/48 (2006.01); A61K 38/29 (2006.01); A61Q 7/00 (2006.01); C12N 9/52 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/635 (2013.01); A61K 8/64 (2013.01); A61K 8/66 (2013.01); A61K 9/0019 (2013.01); A61K 35/28 (2013.01); A61K 38/164 (2013.01); A61K 38/29 (2013.01); A61K 38/4886 (2013.01); A61Q 7/00 (2013.01); C12N 9/1088 (2013.01); C12N 9/50 (2013.01); C12N 9/52 (2013.01); C12N 9/6489 (2013.01); C12Y 205/01018 (2013.01); C12Y 304/24003 (2013.01); C12Y 304/24007 (2013.01); A61K 2800/86 (2013.01); A61K 2800/91 (2013.01); C07K 2319/00 (2013.01); C07K 2319/50 (2013.01); C07K 2319/70 (2013.01);
Abstract

Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.


Find Patent Forward Citations

Loading…